249 related articles for article (PubMed ID: 24028867)
1. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
[TBL] [Abstract][Full Text] [Related]
2. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
3. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
Am J Pathol; 2003 Jan; 162(1):213-8. PubMed ID: 12507904
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
Köhler C; Bista P; Götz J; Schröder H
Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
[TBL] [Abstract][Full Text] [Related]
5. Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau.
Perreault S; Bousquet O; Lauzon M; Paiement J; Leclerc N
J Neuropathol Exp Neurol; 2009 May; 68(5):503-14. PubMed ID: 19525898
[TBL] [Abstract][Full Text] [Related]
6. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
7. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
9. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.
Fox LM; William CM; Adamowicz DH; Pitstick R; Carlson GA; Spires-Jones TL; Hyman BT
J Neuropathol Exp Neurol; 2011 Jul; 70(7):588-95. PubMed ID: 21666499
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
11. Altered function of hippocampal CA1 pyramidal neurons in the rTg4510 mouse model of tauopathy.
Dalby NO; Volbracht C; Helboe L; Larsen PH; Jensen HS; Egebjerg J; Elvang AB
J Alzheimers Dis; 2014; 40(2):429-42. PubMed ID: 24448785
[TBL] [Abstract][Full Text] [Related]
12. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
13. Evidence for accelerated tauopathy in the retina of transgenic P301S tau mice exposed to repetitive mild traumatic brain injury.
Xu L; Ryu J; Nguyen JV; Arena J; Rha E; Vranis P; Hitt D; Marsh-Armstrong N; Koliatsos VE
Exp Neurol; 2015 Nov; 273():168-76. PubMed ID: 26311071
[TBL] [Abstract][Full Text] [Related]
14. Differential accumulation of tau pathology between reciprocal F1 hybrids of rTg4510 mice.
Yanagisawa D; Hamezah HS; Pahrudin Arrozi A; Tooyama I
Sci Rep; 2021 May; 11(1):9623. PubMed ID: 33953293
[TBL] [Abstract][Full Text] [Related]
15. Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Bailey RM; Howard J; Knight J; Sahara N; Dickson DW; Lewis J
Mol Neurodegener; 2014 Jan; 9():8. PubMed ID: 24428919
[TBL] [Abstract][Full Text] [Related]
16. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
17. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.
Santa-Maria I; Diaz-Ruiz C; Ksiezak-Reding H; Chen A; Ho L; Wang J; Pasinetti GM
Neurobiol Aging; 2012 Sep; 33(9):2072-81. PubMed ID: 22054871
[TBL] [Abstract][Full Text] [Related]
18. Effects of alpha-tocopherol on an animal model of tauopathies.
Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
[TBL] [Abstract][Full Text] [Related]
19. Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy.
Yue M; Hanna A; Wilson J; Roder H; Janus C
Neurobiol Aging; 2011 Apr; 32(4):590-603. PubMed ID: 19427061
[TBL] [Abstract][Full Text] [Related]
20. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
